ExaGrid Named a Finalist in SDC Awards 2019
30.10.2019 14:00:00 EET | Business Wire | Press release
ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been named a finalist in the Storage, Digitalisation + Cloud (SDC) Awards 2019. The SDC Awards – the new name for Angel Business Communications' IT awards – is firmly focused on recognizing and rewarding success in the products and services that are the foundation for digital transformation. ExaGrid’s EX Series backup storage appliances with data deduplication is nominated for “Backup Storage Innovation of the Year.” Voting to determine the winner in each category is underway now and closes on 15th November 2019 at 17:30 BST. The results will be revealed at an evening gala in London on 27th November 2019.
ExaGrid has gained the nomination due the EX Series’ uniquely scalable architecture and its specialized deduplication process. ExaGrid is best known for its industry-leading approach to backup storage with unique Landing Zone technology, Adaptive Deduplication approach, and cost-effective scale-out architecture. Managing data growth can cause strain on backup storage and ExaGrid set out to develop the best backup target possible. Through its intelligent hyperconverged storage for backup with data deduplication, ExaGrid helps IT organizations solve three of the most pressing issues they face today: how to protect and manage growing data, how to recover data as quickly as possible, and how to do so at a lower cost.
In data backup, organizations retain weekly, monthly and yearly backups in order to account for regulatory audits, legal discovery and other business reasons. It is not uncommon for organizations to retain 20 to 50 copies of their backup data at different historic points in time. As a result, the total backup storage can be 20 to 50 times greater than the initial primary storage copy. The cost of storage for backup becomes prohibitive and difficult to manage. The value that ExaGrid provides stems from its adaptive approach to deduplication, which offers a 20:1 data deduplication ratio. The ExaGrid system can easily scale to accommodate data growth. ExaGrid’s computing software makes the system highly scalable. Appliances of any size or age can be mixed and matched in a single system with capacities of up to a 2PB full backup plus retention and an ingest rate of up to 432TB per hour, which is the highest in the industry. Once virtualized, they appear as a single system to the backup server, and load balancing of all data across servers is automatic reducing IT staff maintenance and time.
The traditional inline approach to backup storage only stores deduplicated data. Therefore, both backups and restores are slow as data is deduplicated and rehydrated. As data grows, no additional compute resources are added – so the backup window grows until backups must be abandoned as they are cutting into production hours. Only an expensive, disruptive, forklift upgrade can resolve the longer backup windows. Instead, ExaGrid writes data straight to a disk Landing Zone for the fastest backups, while deduplication happens in parallel. The most recent backup is kept in undeduplicated form in its Landing Zone for the fastest restores and instant VM recovery, since no rehydration is necessary. Long-term retention data is stored deduplicated in the repository, which is a separate section of the appliance.
“ExaGrid’s nomination demonstrates the importance of innovation in the backup storage space and the need for a continued focus on data storage efficiency and cost savings,” said Bill Andrews, CEO and President of ExaGrid. “ExaGrid’s unique scale-out storage architecture provides all compute, network and storage resources for a fixed-length backup window as data grows. This provides essential time savings for strained IT staff. Our approach also eliminates expensive forklift upgrades and planned product obsolescence, which reduces the total cost of ownership for organizations looking to save storage space in their backup environment.”
ExaGrid supports all backup typologies including private cloud, offsite data center, third-party data center, third-party cloud, public cloud, and can operate in a pure hybrid environment.
Lastly, ExaGrid supports a wide variety of backup applications, utilities, and database dumps, such as Veeam, Commvault, Veritas NetBackup, IBM Spectrum Protect, HYCU, Zerto, Acronis and many others. ExaGrid allows multiple approaches within the same environment. An organization can use one backup application for its physical servers, a different backup application or utility for its virtual environment, and also perform direct Microsoft SQL or Oracle RMAN database dumps – all to the same ExaGrid system. This approach allows customers to use the backup application and utilities of their choosing, use best-of-breed backup applications and utilities, and choose the right backup application and utility for each specific use case. If the customer chooses to change their backup application in the future, the ExaGrid system will still work, protecting the initial investment.
About ExaGrid
ExaGrid provides intelligent hyperconverged storage for backup with data deduplication, a unique Landing Zone, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191030005092/en/
Contact information
Stacey Foster
ExaGrid
sfoster@exagrid.com
508-898-2872 x0248
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
